|
Report Date : |
31.12.2014 |
IDENTIFICATION DETAILS
|
Name : |
ACHÉ LABORATÓRIOS FARMACÊUTICOS S/A |
|
|
|
|
Registered Office : |
Rodovia Presidente Dutra, S/N°. KM 222,2 - Porto Da Igreja, 07034-904 - Guarulhos/Sp |
|
|
|
|
Country : |
Brazil |
|
|
|
|
Financials (as on) : |
31.12.2013 |
|
|
|
|
Date of Incorporation : |
21.03.1961 |
|
|
|
|
Legal Form : |
Privately Held Corporation |
|
|
|
|
Line of Business : |
Manufacture of Pharmaceuticals. |
|
|
|
|
No. of Employees : |
2784 Employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2014
|
Country Name |
Previous Rating (30.06.2014) |
Current Rating (30.09.2014) |
|
Brazil |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
BRAZIL - ECONOMIC
OVERVIEW
Characterized by large and
well-developed agricultural, mining, manufacturing, and service sectors, and a rapidly
expanding middle class, Brazil's economy outweighs that of all other South
American countries, and Brazil is expanding its presence in world markets.
Since 2003, Brazil has steadily improved its macroeconomic stability, building
up foreign reserves, and reducing its debt profile by shifting its debt burden
toward real denominated and domestically held instruments. In 2008, Brazil
became a net external creditor and two ratings agencies awarded investment
grade status to its debt. After strong growth in 2007 and 2008, the onset of
the global financial crisis hit Brazil in 2008. Brazil experienced two quarters
of recession, as global demand for Brazil's commodity-based exports dwindled
and external credit dried up. However, Brazil was one of the first emerging
markets to begin a recovery. In 2010, consumer and investor confidence revived
and GDP growth reached 7.5%, the highest growth rate in the past 25 years.
Rising inflation led the authorities to take measures to cool the economy;
these actions and the deteriorating international economic situation slowed
growth in 2011-13. Unemployment is at historic lows and Brazil's traditionally
high level of income inequality has declined for each of the last 14 years.
Brazil's historically high interest rates have made it an attractive
destination for foreign investors. Large capital inflows over the past several
years have contributed to the appreciation of the currency, hurting the
competitiveness of Brazilian manufacturing and leading the government to intervene
in foreign exchange markets and raise taxes on some foreign capital inflows.
President Dilma ROUSSEFF has retained the previous administration's commitment
to inflation targeting by the central bank, a floating exchange rate, and
fiscal restraint.
|
Source
: CIA |
ACHÉ LABORATÓRIOS
FARMACÊUTICOS S/A
|
MAIN ADDRESS: |
RODOVIA PRESIDENTE DUTRA, S/N°. KM 222,2 - PORTO DA IGREJA |
|
ZIP CODE/CITY: |
07034-904 - GUARULHOS/SP |
|
|
|
|
PHONE: |
11 2608-6467 |
|
FAX: |
11 2608-6467 |
|
E-MAIL: |
|
|
WEB SITE: |
|
BRANCHES: |
|
|
|
|
|
ADDRESS: |
RUA MACHADO BITTENCOURT,190 - VILA CLEMENTINO |
|
ZIP CODE/CITY: |
04044-000 SÃO PAULO/SP |
|
MAIN ACTIVITIES: |
|
MANUFACTURE OF PHARMACEUTICALS. |
|
LEGAL FORM: |
PRIVATELY
HELD CORPORATION |
|
|
|
|
INCORPORATION DATE: |
21/03/1961 |
|
REGISTER DATE: |
21/03/1961 |
|
BALANCE SHEET FILING DATE: |
31/12 |
|
TAX CONTRIBUTOR NUMBER(CNPJ): |
60.659.463/0001-91 |
|
STATE REGISTER: |
336.059.160.110 |
|
|
|
|
SHARE CAPITAL: |
R$
440.959.484,00 |
|
LAST REGISTER OF CAPITAL: |
31/12/2012 |
|
BOARD OF DIRECTORS:
|
|
|
|
|
|
CELSO PEREIRA SUSTOVICH |
DIRECTOR |
|
WILSON ROBERTO DE FARIAS |
DIRECTOR |
|
VANIA DE AZEVEDO NOGUEIRA DE ALCANTARA MACHADO |
DIRECTOR |
|
MANOEL ARRUDA NASCIMENTO |
OPERATIONS DIRECTOR |
|
SIDINEI RIGHINI |
DIRECTOR |
|
LUCIANA GUALDA DOS SANTOS SASSO |
DIRECTOR |
|
THE DIRECTORS ARE AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY. |
|
SHAREHOLDERS /
PARTNERS: |
|
|
|
|
|
VINCITORE FUNDO INVEST EM PARTICIPAÇÕES |
33,33% |
|
LAJOTA FUNDO INVEST EM PARTICIPAÇÕES |
33,33% |
|
INFINITY FUNDO INVEST EM PARTICIPAÇÕES |
33,33% |
|
AFFILIATES /
SUBSIDIARIES: |
|
|
|
|
|
BIOSINTÉTICA FARMACÊUTICA LTDA |
99,99% |
|
INDUSTRIA FARMACEUTICA MELCON DO BRASIL S/A |
50,00% |
|
ACHÉ'S HISTORY DATES BACK TO 1961, ORIGINALLY NAMED PRODOCTOR PRODUTOS
FARMACÊUTICOS, IN SÃO PAULO, WITH THE UNION OF EX-ADVERTISERS ADALMIRO
DELLAPE BAPTISTA, ANTONIO GILBERTO DEPIERE AND VICTOR SIAULYS (CURRENT
PRESIDENT OF THE ADMINISTRATIVE COUNCIL). IN THE FOLLOWING YEAR, THEY ACHIER
ACHÉ, CREATED IN THE 30'S BY THE FRENCH PHILLIPPE ACHÉ, IN RIBEIRÃO PRETO,
INTERIOR OF SÃO PAULO. TWELVE YEARS LATER, THE COMPANY ACQUIRED BRACCO-NOVOTERÁPICA, FROM
ITALY, AND, IN 1982, OBTAINED THE RIGHT TO PRODUCE AND TRADE THE MEDICINES OF
PARKE-DAVIS, AMERICAN MULTINATIONAL, BELONGED TO WARNER-LAMBERT GROUP. IN
1988, ACHÉ CREATED PRODOME IN JOINT-VENTURE WITH MERCK SHARP & DOHME,
DEEMED THE LARGEST PHARMACEUTICAL LABORATORY WORLDWIDE, AT THAT TIME. RECENTLY, THE COMPANY ACQUIRED 42% OF THE CAPITAL OF THE AMERICAN
MULTINATIONAL SCHERING-PLOUGH, HEADQUARTERED IN RIO DE JANEIRO. NOWADAYS ACHE
IS CONSOLIDATED AS THE LARGEST LABORATORY WITH 100% OF DOMESTIC CAPITAL IN BRAZIL.
THE SUBJECT OWNS 2.952 EMPLOYEES, OF WHICH 1.687 ARE ADVERTISERS, SHOWING THE
NOVELTIES TO OVER 145.000 DOCTORS NATIONWIDE. THE WORKFORCE OF THE ACHÉ'S
ADVERTISERS IS DISTRIBUTED AMONG ITS HEADQUARTERS AND ITS 17 BRANCHES
THROUGHOUT BRAZIL. ACHE SHOWS THE WORKFORCE OF A COMPANY WHICH SHOWED IN 2000, A NET
REVENUE OF R$ 454 MILLION AND GROSS PROFIT OF R$ 307 MILLION. THE GOAL FOR
THE NEXT YEARS IS EVEN MORE CHALLENGING, AS THE COMPANY IS INCREASING ITS
PRODUCTION ARE THAT CURRENTLY COMPRISE OF 51.436 SQ MTS. AS PER THE "PROJETO PARMA", THE NEW PLANT (WHICH INVESTMENTS
REACHED US$ 145 MILLION), TO BE INAUGURATED IN 2005 SHALL PRODUCE, ANNUALLY,
OVER 200 MILLION OF MEDICINES. THE INDUSTRIAL FACILITIES WILL COUNT ON WITH
ALL REQUIRED INFRASTRUCTURE SUCH AS TECHNOLOGY AND TRAINING TO OPERATE
ACCORDINGLY AS A WORLDWIDE COMPANY. IN 1983, ACHÉ ACQUIRED DIVISÃO BRASILEIRA DA MULTINACIONAL PARKE
DAVIS. IN THE SAME YEAR ACHÉ JOINED TO MERCK SHARP & DOHME IN A JOINT
VENTURE RESULTING BINACIONAL PRODOME. TRHEE YEARS LATER, IN 1990, O ACHÉ ACQUIRED 42% THE CONTROL OF
MULTINACIONAL SCHERING-PLOUGH. IN 2001, ACHÉ ACHIEVED THE CERTIFICATES: ISO 14001, REFERING TO
ENVIRONMENTAL MANAGEMENT AND OHSAS 18001, WORK SECURITY. ON AUGUST 30, 2003 THE COMPANY ASTA MÉDICA LTDA, WAS TAKEN OVER BY
ACHÉ LABORATÓRIOS FARMACÊUTICOS S/A. IN 2005 ACHE ACQUIRED BIOSINTÉTICA FARMACÊUTICA AND STARTED WORKING
WITH MORE THAN 250 THERAPEUTICAL OPTIONS. FURTHER DETAILS ABOUT THE SUBJECT'S HISTORY ARE SO FAR NOT KNOWN. |
|
PROTESTS: |
|
13 PROTESTS,TOTAL AMOUNT R$
53.865,74 |
|
DATE OF FIRST PROTEST:
03/2014 R$ 882,16 |
|
DATE OF HIGHEST PROTEST:
12/2014 R$ 39.679,53 |
|
DETAILS OF LATEST PROTESTS: |
|
NOTARY OFFICE: |
DATE: |
VALUE: |
|
1º CARTÓRIO DE GUARULHOS/SP |
25/09/2014 |
R$ 571,33 |
|
2º CARTORIO DE GUARULHOS/SP |
23/12/2014 |
R$ 1.202,39 |
|
1º CARTÓRIO DE GUARULHOS/SP |
23/12/2014 |
R$ 327,71 |
|
2º CARTÓRIO DE GUARULHOS/SP |
10/12/2014 |
R$ 39.679,53 |
|
2º CARTÓRIO DE GUARULHOS/SP |
11/08/2014 |
R$ 1.049,80 |
|
LAWSUITS: |
|
|
|
|
DATE: |
COURT OF LAW: |
|
1 |
EXECUTIVE LAWSUIT |
07/03/14 |
7ª VARA DE GUARULHOS/SP |
|
1 |
STATE LAWSUIT |
24/10/11 |
2ª VARA DE GUARULHOS/SP |
|
1 |
MONITORY SUIT |
07/03/14 |
7ª VARA DE GUARULHOS/SP |
|
1 |
FEDERAL LAWSUIT |
06/08/13 |
3ª VARA DE GUARULHOS/SP |
|
GENERAL BALANCE SHEETS AS OF 31/12/2013, 31/12/2012 AND 31/12/2011. |
|
(FIGURES ARE IN THOUSANDS OF REAIS ). |
|
ASSETS |
|
|
|
|
CURRENT: |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
|
|
|
|
|
CASH AND BANKS |
262.794 |
124.791 |
133.319 |
|
CLIENTS |
211.760 |
168.103 |
145.770 |
|
INVENTORY |
137.693 |
118.587 |
112.057 |
|
PRE PAID EXPENSES |
25.381 |
14.668 |
15.781 |
|
OTHER CREDITS |
15.342 |
6.709 |
11.740 |
|
DIVIDENDS RECEIVABLES |
|
|
128.922 |
|
RECOVERABLE TAXES |
1.601 |
2.045 |
11.294 |
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL CURRENT ASSETS |
654.571 |
434.903 |
558.883 |
|
LONG-TERM
RECEIVABLES: |
|
|
|
|
|
|
|
|
|
JUDICIAL DEPOSITS |
60.105 |
49.791 |
13.655 |
|
DEFERRED TAXES |
|
|
69.224 |
|
RECOVERABLE TAXES |
2.365 |
1.215 |
1.614 |
|
OTHER CREDITS |
3.688 |
1.914 |
1.432 |
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL LONG-TERM RECEIVABLES |
66.158 |
52.920 |
85.925 |
|
FIXED ASSETS: |
|
|
|
|
|
|
|
|
|
INVESTMENTS |
471.452 |
606.467 |
590.310 |
|
FIXED ASSETS |
528.372 |
505.183 |
497.853 |
|
INTANGIBLE |
26.712 |
27.746 |
28.919 |
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL FIXED ASSETS |
1.026.536 |
1.139.396 |
1.117.082 |
|
|
================ |
================ |
================ |
|
TOTAL ASSETS |
1.747.265 |
1.627.219 |
1.761.890 |
|
LIABILITIES: |
|
|
|
|
CURRENT: |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
|
|
|
|
|
SUPPLIERS |
29.971 |
33.019 |
25.504 |
|
LOANS AND FINANCING |
28.750 |
67.532 |
71.262 |
|
SOCIAL / LABOR OBLIGATIONS |
42.773 |
40.099 |
36.381 |
|
TRIBUTARY OBLIGATIONS |
87.552 |
61.084 |
20.529 |
|
DIVIDENDS |
|
|
150.000 |
|
ACCOUNTS PAYABLE |
5.477 |
5.542 |
5.835 |
|
OTHER PROVISIONS |
9.194 |
7.666 |
4.182 |
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL CURRENT LIABILITIES |
203.717 |
214.942 |
313.693 |
|
LONG TERM
LIABILITIES: |
|
|
|
|
|
|
|
|
|
LOANS AND FINANCING |
127.824 |
118.849 |
135.225 |
|
PROVISION FOR CONTINGENCIES |
110.260 |
98.316 |
71.187 |
|
TRIBUTARY OBLIGATIONS |
27.284 |
29.516 |
70.895 |
|
OTHER |
18.153 |
30.531 |
15.943 |
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL LONG TERM LIABILITIES |
283.521 |
277.212 |
293.250 |
|
NET EQUITY: |
|
|
|
|
|
|
|
|
|
SHARE CAPITAL |
440.959 |
440.959 |
407.310 |
|
CAPITAL RESERVES |
174.212 |
174.212 |
174.212 |
|
REVALUATION RESERVES |
5.527 |
5.856 |
6.061 |
|
PROFIT RESERVES |
501.526 |
371.545 |
389.954 |
|
OTHER COMPREHENSIVE INCOME |
137.803 |
142.493 |
177.410 |
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL NET EQUITY |
1.260.027 |
1.135.065 |
1.154.947 |
|
|
================ |
================ |
================ |
|
TOTAL LIABILITIES |
1.747.265 |
1.627.219 |
1.761.890 |
|
PROFIT AND LOSS ACCOUNTS AS OF 31/12/2013, 31/12/2012 AND 31/12/2011. |
|
( FIGURES ARE IN THOUSANDS OF REAIS ). |
|
|
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
|
|
|
|
|
NET SALES |
1.337.391 |
1.131.130 |
989.365 |
|
(-) COST OF SOLD GOODS |
294.685 |
234.429 |
203.086 |
|
|
---------------- |
---------------- |
---------------- |
|
GROSS PROFIT |
1.042.706 |
896.701 |
786.279 |
|
OPERATING REVENUE (EXPENSE) |
-524.111 |
-380.622 |
-350.742 |
|
FINANCIAL REVENUE(EXPENSE) |
-239 |
2.383 |
9.254 |
|
|
---------------- |
---------------- |
---------------- |
|
OPERATIONAL PROFIT (LOSS) |
518.356 |
518.462 |
444.791 |
|
CONTRIBUTION/INCOME TAX |
-114.542 |
-95.791 |
-64.118 |
|
|
---------------- |
---------------- |
---------------- |
|
NET PROFIT (LOSS) |
403.814 |
422.671 |
380.673 |
|
RATIOS: |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
QUICK RATIO |
2,54 |
|
1,47 |
|
1,42 |
|
|
CURRENT RATIO |
3,21 |
|
2,02 |
|
1,78 |
|
|
ACCOUNTS RECEIVABLE TURNOVER |
6,32 |
TIMES |
6,73 |
TIMES |
6,79 |
TIMES |
|
DAYS' SALES IN RECEIVABLES |
57,00 |
DAYS |
53,50 |
DAYS |
53,04 |
DAYS |
|
INVENTORY TURNOVER |
2,14 |
TIMES |
1,98 |
TIMES |
1,81 |
TIMES |
|
ACCOUNTS PAYABLE PERIOD |
36,61 |
DAYS |
50,71 |
DAYS |
45,21 |
DAYS |
|
RETURN ON ASSETS |
,77 |
TIMES |
,70 |
TIMES |
,56 |
TIMES |
|
SALES TURNOVER ON NET EQUITY |
1,06 |
TIMES |
1,00 |
TIMES |
,86 |
TIMES |
|
NET WORTH TIE-UP |
,42 |
|
,45 |
|
,43 |
|
|
INDEBTEDNESS |
,39 |
|
,43 |
|
,53 |
|
|
EQUITY RATIO |
72,11 |
% |
69,75 |
% |
65,55 |
% |
|
WORKING CAPITAL RATIO |
221,31 |
% |
102,34 |
% |
78,16 |
% |
|
GENERAL SOLVENCY |
3,59 |
|
3,31 |
|
2,90 |
|
|
RETURN ON NET EQUITY |
32,05 |
% |
37,24 |
% |
32,96 |
% |
|
RETURN ON SALES (PROFIT MARGIN) |
30,19 |
% |
37,37 |
% |
38,48 |
% |
|
GROSS PROFIT MARGIN |
77,97 |
% |
79,27 |
% |
79,47 |
% |
|
OPERATIONAL RESULT |
38,76 |
% |
45,84 |
% |
44,96 |
% |
|
SALES TURNOVER ON LIABILITIES |
6,56 |
TIMES |
5,26 |
TIMES |
3,15 |
TIMES |
|
FOREIGN CURRENCY ON ASSETS |
|
|
|
|
|
|
|
FOREIGN CURRENCY ON LIABILITIES |
|
|
|
|
|
|
|
EXCHANGE RATE: |
|
|
US$ 1,00 = R$ 2,68 |
- OFFICIAL RATE ON 26/12/2014 |
|
US$ 1,00 = R$ 2,34 |
- OFFICIAL RATE ON 31/12/2013 |
|
US$ 1,00 = R$ 2,04 |
- OFFICIAL RATE ON 31/12/2012 |
|
US$ 1,00 = R$ 1,87 |
- OFFICIAL RATE ON 31/12/2011 |
|
COMMENTS ON THE
FINANCIAL INFORMATION: |
|
FOLLOWS ATTACHED WORKSHEET WITH MAIN FINANCIAL RATIOS. THE FIGURES AVAILABLE SHOW A GOOD FINANCIAL STANDING. IT SHOWS GOOD
LIQUIDITY RATIOS AND POSITIVE WORKING CAPITAL, AS WELL AS LOW LEVEL OF
INDEBTEDNESS. IT ALSO SHOWS GROWING SALES AND PROFITABILITY. IT IS WORTH COMMENTING THAT THE COMPANY HAS HIGH FINANCIAL POWER AND
OPERATES NORMALLY, MANAGING WITH EFFICIENCY ITS CAPITAL NEEDS, NOT SHOWING
SIGNS OF FINANCIAL PROBLEMS SO FAR. |
|
REAL ESTATE: |
OWNED PREMISES ARE VALUED AT R$ 402.682.000,00
|
VEHICLES: |
OWNED VEHICLES ARE VALUED AT R$ 139.000,00
|
MACHINES: |
OWNED MACHINES AND EQUIPMENTS ARE VALUED AT R$ 52.027.000,00
|
INSURANCE COMPANY: |
ITAÚ SEGUROS S/A 90% AND BRADESCO 10% |
|
COVERAGE: |
RISCOS NOMEADOS |
|
|
BRANCH/PHONE: |
CITY: |
|
BANCO ITAÚ S/A |
11 3708-2537 |
SÃO PAULO/SP |
|
BANCO BRADESCO S/A |
11 2178-4682 |
SÃO PAULO/SP |
|
BANCO DO BRASIL S/A |
11 2128-7184 |
SÃO PAULO/SP |
|
REMARKS: IN BRAZIL THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION
OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE
ARE UNABLE TO PROVIDE ANY BANKING DETAILS. ACCORDING TO THE CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY
HAS NO RETURNED CHECKS UP TO DATE. (IN THE TERMS OF "CIRCULAR 1682
BRAZILIAN CENTRAL BANK"). |
|
THE SUBJECT IS ENGAGED IN THE MANUFACTURE OF MEDICINES FOR HUMAN USE. |
|
IMPORT AND
EXPORT: |
IMPORTS FROM:
|
URUGUAY, SWITZERLAND, HUNGARY, SLOVENIA, CHINA |
EXPORTS TO:
|
DOES NOT HAVE. |
|
MAIN CLIENTS: |
|
|
|
|
|
|
|
DOMESTIC
CLIENTS: |
|
PHONE: |
|
D CENTER DISTRIBUIDORA LTDA |
|
16 3603-0111 |
|
DIMED S/A DISTRIB. DE MEDICAMENTOS |
|
51 3218-9500 |
|
DISTRIBUIDORA DE MEDICAMENTOS ANB FARMA LTDA |
|
41 3072-8000 |
|
DISTRIBUIDORA DE MEDICAMENTOS SANTA CRUZ LTDA |
|
11 3040-7500 |
|
DISTRIBUIDORA FARMACÊUTICA PANARELLO LTDA |
|
62 4013-2000 |
|
DROGARIA SÃO PAULO S/A |
|
11 3274-7416 |
|
NAZARIA DISTRIB. PRODS FARMACÊUTICOS LTDA |
|
86 3216-4600 |
|
PROFARMA DIST. PROD. FARMÊUTICOS LTDA |
|
21 4009-0200 |
|
SERVIMED COMERCIAL LTDA |
|
14 2106-7205 |
|
STAFF: |
|
|
|
THE COMPANY HAS: 2784 EMPLOYEE(S) |
|
THE SUBJECT IS A WELL-ESTABLISHED COMPANY, OPERATING SINCE 1961. IT IS
A LEADING COMPANY IN ITS LINE OF BUSINESS, OPERATES WITH A CLEAR TRADE
HISTORY AND A GOOD REPUTATION. THE COMPANY HAS TRADE RELATIONS WITH SEVERAL SUPPLIERS IN BRAZIL. THE
SUPPLIERS EXTEND CREDIT FACILITIES TO THE SUBJECT IN TERMS AND AMOUNTS ACCORDING
TO THE COMPANY'S NEEDS AND SO FAR NO PAYMENT PROBLEMS ARE NOTED. THE LAWSUITS REPORTED ARE NOT RELATED WITH TRADE DEBTS. THEY ARE
RELATED TO TAX DEBTS THAT FOR ANY REASON THE COMPANY HAS NOT YET PAID.
NEVERTHELESS WE POINT OUT THAT THE SAID LAWSUITS DO NOT AFFECT THE COMPANY'S
TRADE REPUTATION. THE PROTESTS ARE IRRELEVANT. |
|
MAIN SUPPLIERS: |
|
|
|
|
|
|
|
DOMESTIC
SUPPLIERS: |
|
|
|
A.W. FABER CASTELL S/A |
|
|
|
AGILENT TECHNOLOGIES BRASIL LTDA |
|
11 4197-3500 |
|
ALCAN EMBALAGENS DO BRASIL LTDA |
|
11 4512-7000 |
|
ALD AUTOMOTIVE |
|
11 3147-4826 |
|
BPG EMBALAGENS LTDA |
|
11 4048-1255 |
|
COLORCON DO BRASIL LTDA |
|
11 4617-8640 |
|
DSM PRODS NUTRICIONAIS BR. LTDA |
|
11 3760-6493 |
|
IQ SOLUÇÕES & QUIMICA S/A |
|
11 2195-9157 |
|
MAGISTRAL IMPRESSORA INDUSTRIAL LTDA |
|
41 2141-0408 |
|
ROSELI DA SILVA PASCHOALATTO COM RELOGIOS - EPP |
|
|
|
SAG DO BRASIL S/A |
|
11 3147-5780 |
|
SIKA S/A |
|
|
|
SOBRAL INVICTA S/A |
|
|
|
FOREIGN
SUPPLIERS: |
COUNTRY: |
|
|
BASELUX |
SWITZERLAND |
|
|
CAPE INTERNATIONAL LLC |
URUGUAI |
|
|
CHEMICAL WORKS GEDEON RICHTER |
HUNGARY |
|
|
CIA COMERCIALIZADORA INTERNACIONAL S/A |
URUGUAY |
|
|
DEBIO RECHERCHECE PHARMA S/A |
SWITZERLAND |
|
|
FISCHER CHEMICALS |
CHINA |
|
|
LEK PHARMA AND CHEM COMP |
SLOVENIA |
|
|
SPAR CHEMICAL ESTABLISSEMENT |
SWITZERLAND |
|
|
PAYMENT HISTORY: |
|
17 SUPPLIERS REPORTED PAYMENTS: |
|
TOTAL AMOUNT: R$ 1.051.058,00 |
|
|
|
AMOUNT OF INVOICES PAID: 67 |
|
TOTAL OF PROMPT PAYMENTS: 100% |
|
HIGHEST INVOICE: R$ 83.808,00 |
|
HIGHEST CREDIT: R$ 83.808,00 |
|
|
|
OUTSTANDING
INVOICES DUE WITHIN THE NEXT 30 DAYS: |
|
--------------------------- |
SUPPLIERS: |
INVOICES: |
TOTAL AMOUNT: |
|
DUE WITHIN 30 DAYS |
1 |
1 |
R$ 4.326,30 |
|
THE SUBJECT IS A WELL-ESTABLISHED COMPANY IN BUSINESS FOR SEVERAL
YEARS. UP TO DATE IT HAS A GOOD
FINANCIAL STANDING, A CLEAR TRADE HISTORY AND GOOD PAYMENT BEHAVIOUR. BASED ON THE OVERALL INFORMATION AVAILABLE IT IS BELIEVED THAT GOOD
TRADE RELATIONS MAY BE ESTABLISHED. CREDIT FACILITIES MAY BE EXTENDED WITHIN
TERMS AND AMOUNTS ADEQUATE TO THE COMPANY'S SIZE AND FINANCIAL STRENGTH. HIGHER AMOUNTS CAN BE GRANTED DEPENDING ON THE IMPORTANCE OF THE
BUSINESS TO BE ESTABLISHED WITH THE SUBJECT. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.75 |
|
|
1 |
Rs.98.88 |
|
Euro |
1 |
Rs.77.32 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.